跳至主要内容
临床试验/NCT00629213
NCT00629213已完成3 期

Metabolic Syndrome and Its Single Traits as Risk Factors of Diabetes in People With Impaired Glucose Tolerance: The STOP-NIDDM Trial

GWT-TUD GmbH1 个研究点 分布在 1 个国家目标入组 1,429 人开始时间: 2008年3月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
GWT-TUD GmbH
入组人数
1,429
试验地点
1
主要终点
Incidence of newly diagnosed type 2 diabetes

研究概览

简要总结

The aim of the study was to analyse the independent and joint effects of the components of the metabolic syndrome (MetS) on the incidence of diabetes in people with impaired glucose tolerance (IGT) and to assess the effect of acarbose by MetS status.

Double-blind placebo controlled trial, 1,368 patients, follow-up time 3.3 years. MetS by ATP III definition with fasting plasma glucose of ≥ 6.1 mmol/l as limit for impaired fasting glucose (IFG).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • High risk population
  • Age 40 to 70 yrs.
  • BMI > 25 and < 40; FPG >5.5 mmol/l and < 7.8 mmol/l; IGT in OGGT

排除标准

  • Known type 2 diabetes
  • Drug intake affecting glucose tolerance
  • Any cardiovascular events within the last 6 months

研究组 & 干预措施

1

Active Comparator

干预措施: acarbose (Drug)

2

Placebo Comparator

干预措施: placebo (Drug)

结局指标

主要结局

Incidence of newly diagnosed type 2 diabetes

次要结局

  • newly diagnosed hypertension

研究者

发起方
GWT-TUD GmbH
申办方类型
Other

研究点 (1)

Loading locations...

相似试验